Is AMPK the savior of the failing heart?

Trends in Endocrinology and Metabolism

Volumn 26, Issue 1, 2015, Pages 40-48

  Kim, Ty T ^a   Dyck, Jason R B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

AMP activated protein kinase (AMPK); Cardiac metabolism; Myocardial ATP production; Systolic heart failure

Indexed keywords

FATTY ACID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TRANSCRIPTION FACTOR FOXO; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; AICA RIBONUCLEOTIDE; METFORMIN; RIBONUCLEOTIDE;

ENERGY METABOLISM; ENERGY YIELD; ENZYME ACTIVATION; GLUCOSE UTILIZATION; HEART FAILURE; HUMAN; METABOLIC DISORDER; NONHUMAN; REGULATORY MECHANISM; REVIEW; SYSTOLIC HEART FAILURE; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; GENETICS; HEART; HEART MUSCLE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ENERGY METABOLISM; HEART; HEART FAILURE; HUMANS; METFORMIN; MYOCARDIUM; RIBONUCLEOTIDES;

EID: 84920596800     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.11.001     Document Type: Review

References (112)

1. Go A.S., et al. Heart disease and stroke statistics: 2014 update: a report from the American Heart Association. Circulation 2014, 129:e28-e292.
2. Owan T.E., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 2006, 355:251-259.
3. Yancy C.W., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013, 128:240-327.
4. Arnold J.M.O., et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can. J. Cardiol. 2006, 22:23-45.
5. Kannel W.B., et al. Profile for estimating risk of heart failure. Arch. Intern. Med. 1999, 159:1197-1204.
6. Ezekowitz J.A., et al. Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics?. Eur. J. Heart Fail. 2011, 13:142-147.
7. Ezekowitz J.A., et al. Impact of specialist follow-up in outpatients with congestive heart failure. CMAJ 2005, 172:189-194.
8. Johnson F.L. Pathophysiology and etiology of heart failure. Cardiol. Clin. 2014, 32:9-19.
9. Hunt S.A., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:391-479.
10. Peterson P.N., et al. Treatment and risk in heart failure: gaps in evidence or quality?. Circ. Cardiovasc. Qual. Outcomes 2010, 3:309-315.
11. Paulus W.J., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur. Heart J. 2007, 28:2539-2550.
12. Abhayaratna W.P., et al. Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey. Heart 2006, 92:1259-1264.
13. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur. Heart J. 2012, 33:1750-1757. Meta-analysis Global Group in Chronic Heart Failure.
14. Kho C., et al. Altered sarcoplasmic reticulum calcium cycling: targets for heart failure therapy. Nat. Rev. Cardiol. 2012, 9:717-733.
15. Orogo A.M., Gustafsson Å.B. Cell death in the myocardium: my heart won't go on. IUBMB Life 2013, 65:651-656.
16. Mann D.L., Spinale F.G. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation 1998, 98:1699-1702.
17. El Desoky E.S. Drug therapy of heart failure: an immunologic view. Am. J. Ther. 2011, 18:416-425.
18. Horgan S., et al. Murine models of diastolic dysfunction and heart failure with preserved ejection fraction. J. Card. Fail. 2014, Published online September 12, 2014. http://dx.doi.org/0.1016/j.cardfail.2014.09.001.
19. Lygate C.A., et al. Investigating cardiac energetics in heart failure. Exp. Physiol. 2013, 98:601-605.
20. Lopaschuk G.D., et al. Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 2010, 90:207-258.
21. Stanley W.C., et al. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 2005, 85:1093-1129.
22. Fillmore N., Lopaschuk G.D. Targeting mitochondrial oxidative metabolism as an approach to treat heart failure. Biochim. Biophys. Acta 2013, 1833:857-865.
23. Lopaschuk G.D., et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim. Biophys. Acta 1994, 1213:263-276.
24. Taegtmeyer H., et al. Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann. N. Y. Acad. Sci. 2004, 1015:202-213.
25. Dhahri W., et al. Chronic high-fat diet-induced obesity decreased survival and increased hypertrophy of rats with experimental eccentric hypertrophy from chronic aortic regurgitation. BMC Cardiovasc. Disord. 2014, 14:123.
26. Neglia D., et al. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H3270-H3278.
27. Bround M.J., et al. Cardiomyocyte ATP production, metabolic flexibility, and survival require calcium flux through cardiac ryanodine receptors in vivo. J. Biol. Chem. 2013, 288:18975-18986.
28. Neubauer S. The failing heart: an engine out of fuel. N. Engl. J. Med. 2007, 356:1140-1151.
29. Hardie D. The AMP-activated protein kinase pathway: new players upstream and downstream. J. Cell Sci. 2004, 1:5479-5487.
30. Balteau M., et al. AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2014, 307:H1120-H1133.
31. Hardie D.G., Carling D. The AMP-activated protein kinase: fuel gauge of the mammalian cell?. Eur. J. Biochem. 1997, 246:259-273.
32. Dolinsky V.W., Dyck J.R.B. Role of AMP-activated protein kinase in healthy and diseased hearts. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:2557-2569.
33. Kudo N., et al. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J. Biol. Chem. 1995, 270:17513-17520.
34. Luiken J.J., et al. Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes 2003, 52:1627-1634.
35. Fillmore N., et al. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br. J. Pharmacol. 2014, 171:2080-2090.
36. Park S.H., et al. Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J. Appl. Physiol. 2002, 92:2475-2482.
37. Marsin A.S., et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr. Biol. 2000, 10:1247-1255.
38. Young M.E., et al. Activation of glycogen phosphorylase and glycogenolysis in rat skeletal muscle by AICAR: an activator of AMP-activated protein kinase. FEBS Lett. 1996, 382:43-47.
39. Russell R.R., 3rd, et al. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am. J. Physiol. 1999, 277:H643-H649.
40. Kubli D.A., Gustafsson A.B. Cardiomyocyte health: adapting to metabolic changes through autophagy. Trends Endocrinol. Metab. 2014, 25:156-164.
41. Patten I.S., Arany Z. PGC-1 coactivators in the cardiovascular system. Trends Endocrinol. Metab. 2012, 23:90-97.
42. Steinberg G.R., Kemp B.E. AMPK in health and disease. Physiol. Rev. 2009, 89:1025-1078.
43. St-Pierre J., et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006, 127:397-408.
44. Jäger S., et al. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:12017-12022.
45. Lagouge M., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
46. Schilling J., Kelly D.P. The PGC-1 cascade as a therapeutic target for heart failure. J. Mol. Cell. Cardiol. 2011, 51:578-583.
47. Ronnebaum S.M., Patterson C. The FoxO family in cardiac function and dysfunction. Annu. Rev. Physiol. 2010, 72:81-94.
48. Sengupta A., et al. FoxO transcription factors promote autophagy in cardiomyocytes. J. Biol. Chem. 2009, 284:28319-28331.
49. Kops G.J., et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002, 419:316-321.
50. Puigserver P., et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003, 423:550-555.
51. Philip-Couderc P., et al. Forkhead transcription factors coordinate expression of myocardial KATP channel subunits and energy metabolism. Circ. Res. 2008, 102:e20-e35.
52. Armoni M., et al. FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. J. Biol. Chem. 2006, 281:19881-19891.
53. Daitoku H., et al. Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR. Diabetes 2003, 52:642-649.
54. Sengupta A., et al. FoxO1 and FoxM1 transcription factors have antagonistic functions in neonatal cardiomyocyte cell-cycle withdrawal and IGF1 gene regulation. Circ. Res. 2013, 112:267-277.
55. Dixit M., et al. Shear stress-induced activation of the AMP-activated protein kinase regulates FoxO1a and angiopoietin-2 in endothelial cells. Cardiovasc. Res. 2008, 77:160-168.
56. Kim A.S., et al. AMP-activated protein kinase: a core signalling pathway in the heart. Acta Physiol. 2009, 196:37-53.
57. Tian R., et al. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001, 104:1664-1669.
58. Huang X., et al. Regulatory effect of AMP-activated protein kinase on pulmonary hypertension induced by chronic hypoxia in rats: in vivo and in vitro studies. Mol. Biol. Rep. 2014, 41:4031-4041.
59. Nishino Y., et al. Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection. Cardiovasc. Res. 2004, 61:610-619.
60. Kim M., et al. AMPK isoform expression in the normal and failing hearts. J. Mol. Cell. Cardiol. 2012, 52:1066-1073.
61. Lu T.M., et al. Downregulation of Sirt1 as aging change in advanced heart failure. J. Biomed. Sci. 2014, 21:57.
62. Arad M., et al. AMP-activated protein kinase in the heart: role during health and disease. Circ. Res. 2007, 100:474-488.
63. Dyck J.R., Lopaschuk G.D. AMPK alterations in cardiac physiology and pathology: enemy or ally?. J. Physiol. 2006, 574:95-112.
64. Russell R.R., 3rd, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J. Clin. Invest. 2004, 114:495-503.
65. Zizola C.P., Schulze P.C. Metabolic and structural impairment of skeletal muscle in heart failure. Heart Fail. Rev. 2013, 18:623-630.
66. Stuck B.J., et al. Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J. Biol. Chem. 2008, 283:32562-32569.
67. Ingwall J.S. Energy metabolism in heart failure and remodelling. Cardiovasc. Res. 2009, 81:412-419.
68. Zhang L., et al. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ. Heart Fail. 2013, 6:1039-1048.
69. Zhabyeyev P., et al. Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. Cardiovasc. Res. 2013, 97:676-685.
70. Riehle C., Abel E.D. PGC-1 proteins and heart failure. Trends Cardiovasc. Med. 2012, 22:98-105.
71. Arany Z., et al. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:10086-10091.
72. Wang J., Guo T. Metabolic remodeling in chronic heart failure. J. Zhejiang Univ. Sci. B 2013, 14:688-695.
73. Li X.N., et al. Activation of the AMPK-FOXO3 pathway reduces fatty acid-induced increase in intracellular reactive oxygen species by upregulating thioredoxin. Diabetes 2009, 58:2246-2257.
74. Wang J., et al. A novel AMPK activator from Chinese herb medicine and ischemia phosphorylate the cardiac transcription factor FOXO3. Int. J. Physiol. Pathophysiol. Pharmacol. 2009, 1:116-126.
75. Kanamori H., et al. Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. Am. J. Pathol. 2013, 182:701-713.
76. Sengupta A., et al. FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress. J. Biol. Chem. 2011, 286:7468-7478.
77. Gross D.N., et al. The role of FoxO in the regulation of metabolism. Oncogene 2008, 27:2320-2336.
78. Beauloye C., et al. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc. Res. 2011, 90:224-233.
79. Cool B., et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006, 3:403-416.
80. Scott J.W., et al. Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chem. Biol. 2008, 15:1220-1230.
81. Kim A.S., et al. A small molecule AMPK activator protects the heart against ischemia-reperfusion injury. J. Mol. Cell. Cardiol. 2011, 51:24-32.
82. Timmermans A.D., et al. A-769662 potentiates the effect of other AMP-activated protein kinase activators on cardiac glucose uptake. Am. J. Physiol. Heart Circ. Physiol. 2014, 306:H1619-H1630.
83. Zhang L., et al. Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H457-H466.
84. Yin M., et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H459-H468.
85. Wang X.F., et al. Metformin improves cardiac function in rats via activation of AMP-activated protein kinase. Clin. Exp. Pharmacol. Physiol. 2011, 38:94-101.
86. Sasaki H., et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009, 119:2568-2577.
87. Gundewar S., et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ. Res. 2009, 104:403-411.
88. Zhang L., et al. Relationship between 5-aminoimidazole-4-carboxamide-ribotide and AMP-activated protein kinase activity in the perfused mouse heart. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H1235-H1243.
89. Chabowski A., et al. Prolonged AMPK activation increases the expression of fatty acid transporters in cardiac myocytes and perfused hearts. Mol. Cell. Biochem. 2006, 288:201-212.
90. Chan A.Y., et al. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J. Biol. Chem. 2004, 279:32771-32779.
91. Li Y., et al. AMPK inhibits cardiac hypertrophy by promoting autophagy via mTORC1. Arch. Biochem. Biophys. 2014, 558:79-86.
92. Meng R., et al. AMPK activation enhances PPARalpha activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway. Arch. Biochem. Biophys. 2011, 511:1-7.
93. Wang H., et al. Resveratrol in cardiovascular disease: what is known from current research?. Heart Fail. Rev. 2012, 17:437-448.
94. Chan A.Y., et al. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J. Biol. Chem. 2008, 283:24194-24201.
95. Dolinsky V.W., et al. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim. Biophys. Acta 2013, 1832:1723-1733.
96. Beauvieux M-C., et al. Resveratrol mainly stimulates the glycolytic ATP synthesis flux and not the mitochondrial one: a saturation transfer NMR study in perfused and isolated rat liver. Pharmacol. Res. 2013, 78:11-17.
97. Um J-H., et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010, 59:554-563.
98. Rimbaud S., et al. Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS ONE 2011, 6:e26391.
99. Gupta P.K., et al. Protective effect of resveratrol against pressure overload-induced heart failure. Food Sci. Nutr. 2014, 2:218-229.
100. Tanno M., et al. Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J. Biol. Chem. 2010, 285:8375-8382.
101. Lin J.F., et al. Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. Life Sci. 2008, 83:313-317.
102. Gu X.S., et al. Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. Genet. Mol. Res. 2014, 13:323-335.
103. Lopez-Lluch G., et al. Mitochondrial biogenesis and healthy aging. Exp. Gerontol. 2008, 43:813-819.
104. Pouleur H. Diastolic dysfunction and myocardial energetics. Eur. Heart J. 1990, 11(Suppl. C):30-34.
105. Kato M.F., et al. Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. J. Hypertens. 2008, 26:1669-1676.
106. Turdi S., et al. Deficiency in AMP-activated protein kinase exaggerates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J. Mol. Cell. Cardiol. 2011, 50:712-722.
107. Yancy C.W., et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J. Am. Coll. Cardiol. 2006, 47:76-84.
108. El Messaoudi S., et al. Metformin therapy in diabetes: the role of cardioprotection. Curr. Atheroscler. Rep. 2013, 15:314.
109. Ji H., et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007, 448:807-810.
110. Baltgalvis K.A., et al. Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice. Am. J. Physiol. Heart Circ. Physiol. 2014, 306:H1128-H1145.
111. Filippov S., et al. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J. Lipid Res. 2013, 54:2095-2108.
112. Ballantyne C.M., et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J. Am. Coll. Cardiol. 2013, 62:1154-1162.